Retatrutide Phase 3: 24% Weight Loss in TRIUMPH-3

Eli Lilly reported topline results from TRIUMPH-3, the largest Phase 3 study of its triple-agonist peptide retatrutide, showing weight reductions that exceed any previously approved GLP-1 therapy.

The numbers

Across 2,400 participants with obesity but without diabetes, mean weight loss at 48 weeks was:

• 12 mg dose: 24.2% of baseline body weight
• 8 mg dose: 21.7%
• 4 mg dose: 17.4%
• Placebo: 2.9%

For comparison, tirzepatide's SURMOUNT-1 trial showed roughly 22.5% loss at 72 weeks at the highest dose — and retatrutide hit higher numbers in two-thirds the time.

Why it matters

Retatrutide is the first molecule to combine GLP-1, GIP, and glucagon receptor agonism in a single peptide. The glucagon arm is the novel piece: it's thought to increase energy expenditure (calories burned at rest) on top of the appetite-suppressing effects of the other two pathways.

If retatrutide gets FDA approval — Lilly has indicated a 2026 submission — it would become the most aggressive non-surgical weight loss intervention available.

What clinicians are watching

Side effects tracked the rest of the GLP-1 class — predominantly GI, dose-dependent, mostly resolving with continued use. There were no signals of pancreatitis or thyroid issues above placebo rates in this readout, though long-term surveillance will continue.

What's next

• FDA submission expected mid-2026 per Lilly's investor call
• TRIUMPH-4 (cardiovascular outcomes) ongoing, expected 2027
• Compounded availability is unlikely in the near term — retatrutide is not on the FDA shortage list, and Lilly has signaled aggressive enforcement against unauthorized compounders

For people already on tirzepatide and tolerating it well, there's no clinical reason to switch on news of a trial readout. But for treatment-resistant patients, retatrutide could change the calculus once approved.